Close
close
October 1st, 2004

New study to describe potential of Octagam in treating post-partum relapse in multiple sclerosis patients


Results from a new study looking at the efficacy of intravenuous immunoglobulins application in post-partum relapse in multiple sclerosis patients will be presented for the first time at the upcoming European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress, Oct 6-9, in Vienna, Austria.

The GAMPP study (Gammaglobulins Post-Partum Study), will describe the efficacy of postpartal application of Octagam 5% to reduce relapse activity in MS patients during the first months after delivery. This study was completed in January 2004, and is expected to be published by year end.

The GAMPP study was performed under the auspices of the European Charcot foundation . Prof. Judith Haas, Berlin , principal investigator of the study, will present the results on Oct .6 at the satellite symposium of the European Charcot-Foundation entitled, "Effect of post-partum treatments on relapse frequency in MS patients." Please see the symposium details below.

Octapharma is a sponsor for the symposium and will participate in the exhibition at booth # 133. We look forward to seeing you there!



(Please note that clicking on the links above will take you outside of the Octapharma web site)
Charcot Foundation Symposium:
Wednesday, October 06, 2004
12:30 - 14:00 h, Hall E

Effects of post-partum treatments in relapse frequency in MS patients
Chair: O.R. Hommes ( Nijmegen , NL)
P. Soelberg Sørensen ( Copenhagen , DK
12:30 - 12:35 Introduction - O.R. Hommes
12:35 - 12:50

General introduction to the question of MS and pregnancy - A. Achiron ( Tel-Hashomer , IL )
12:50 - 13:05 Presentation of the results of the GAMPP trial: gammaglobulines post pregnancy in multiple sclerosis for prevention of exacerbations after delivery. J. Haas ( Berlin , D)
13:05 - 13:20

Pregnancy in MS: the Pregnancy In Multiple Sclerosis (PRIMS) study - C. Confavreux (Lyon, F)
13:20 - 13:35 The CRAFT protocol: Count Relapses After Finishing Trial - T. Moreau (Dijon, F)
13:35 - 14:00 Discussion


© Octapharma AG, 2004